Berikutnya

Putar otomatis

PI3K and PARP Inhibitors in HR+ Metastatic Breast Cancer

14 Tampilan • 07/03/23
Membagikan
Menanamkan
administrator
administrator
Pelanggan
0

Joyce A. O’Shaughnessy, MD, and Andrew D. Seidman, MD, evaluate treatment options outside of CDK4/6 inhibition, such as PI3-kinase or poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors, for patients with hormone-receptor positive metastatic breast cancer.

Menampilkan lebih banyak
0 Komentar sort Sortir dengan
Komentar Facebook

Berikutnya

Putar otomatis